1. Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Issue 12 (15th October 2021) Authors: Kalff, Anna; Khong, Tiffany; Ramachandran, Malarmathy; Walker, Patricia; Schwarer, Anthony; Roberts, Andrew W.; Campbell, Philip; Filshie, Robin; Norton, Sam; Reynolds, John; Young, Mary; Pierceall, William; Thakurta, Anjan; Guo, Manman; Oppermann, Udo; Wang, Maria; Ren, Yan; Kennedy, Nola; Parek... Journal: Leukemia & lymphoma Issue: Volume 62:Issue 12(2021) Page Start: 2981 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. (21st May 2013) Authors: Mithraprabhu, Sridurga; Khong, Tiffany; Jones, Simon S.; Spencer, Andrew Journal: British journal of haematology Issue: Volume 162:Number 4(2013:Aug.) Page Start: 559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Human myeloma cell‐ and plasma‐derived extracellular vesicles contribute to functional regulation of stromal cells. Issue 13 (5th March 2021) Authors: Reale, Antonia; Carmichael, Irena; Xu, Rong; Mithraprabhu, Sridurga; Khong, Tiffany; Chen, Maoshan; Fang, Haoyun; Savvidou, Ioanna; Ramachandran, Malarmathy; Bingham, Nicholas; Simpson, Richard J.; Greening, David W.; Spencer, Andrew Other Names: Greening David guestEditor.; Simpson Richard guestEditor. Journal: Proteomics Issue: Volume 21:Issue 13/14(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. MDX‐1097 induces antibody‐dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. (3rd February 2015) Authors: Asvadi, Parisa; Cuddihy, Andrew; Dunn, Rosanne D.; Jiang, Vivien; Wong, Mae X.; Jones, Darren R.; Khong, Tiffany; Spencer, Andrew Journal: British journal of haematology Issue: Volume 169:Number 3(2015:May) Page Start: 333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Issue 9 (29th July 2019) Authors: Kalff, Anna; Khong, Tiffany; Mithraprabhu, Sridurga; Bergin, Krystal; Reynolds, John; Bowen, Kathryn M.; Thakurta, Anjan; Guzman, Roberto; Wang, Maria; Couto, Suzana; Ren, Yan; Spencer, Andrew Journal: Leukemia & lymphoma Issue: Volume 60:Issue 9(2019) Page Start: 2143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Issue 9 (29th July 2019) Authors: Horvath, Noemi; Spencer, Andrew; Kenealy, Melita; Joshua, Douglas; Campbell, Philip J; Lee, Je-Jung; Hou, Jian; Qiu, Lugui; Kalff, Anna; Khong, Tiffany; Londhe, Anil; Siggins, Sarah; van Kooten Losio, Maximiliano; Eisbacher, Michael; Prince, H. Miles Journal: Leukemia & lymphoma Issue: Volume 60:Issue 9(2019) Page Start: 2122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma. (18th September 2020) Authors: Mithraprabhu, Sridurga; Kalff, Anna; Gartlan, Kate H.; Savvidou, Ioanna; Khong, Tiffany; Ramachandran, Malarmathy; Cooke, Rachel E.; Bowen, Kathryn; Hill, Geoffrey R.; Reynolds, John; Spencer, Andrew Journal: British journal of haematology Issue: Volume 193:Number 1(2021) Page Start: 160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing. Issue 2 (28th January 2021) Authors: Reale, Antonia; Khong, Tiffany; Mithraprabhu, Sridurga; Savvidou, Ioanna; Hocking, Jay; Bergin, Krystal; Ramachandran, Malarmathy; Chen, Maoshan; Dammacco, Francesco; Ria, Roberto; Silvestris, Francesco; Vacca, Angelo; Reynolds, John; Spencer, Andrew Journal: Leukemia & lymphoma Issue: Volume 62:Issue 2(2021) Page Start: 337 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗